Drug intelligence / Profile preview

Dehydrex

Development stage: Unknown
Lead developer: Valeant Pharmaceuticals
Administration: Ophthalmic

Overview

Dehydrex is a colloidal solution that is slightly hyperosmotic to the corneal stroma and is used in ophthalmology to remove fluid from epithelial cells on the corneal surface. Its primary mechanism of action involves drawing excess fluid out of the corneal epithelium, which can be beneficial in conditions such as corneal dystrophy where fluid accumulation impairs vision. Dehydrex acts through osmotic effects rather than receptor-mediated pharmacology[2].

Brand names: dehydrex

Beyond the preview

Go deeper on Dehydrex.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dehydrex.

Explore the full profile